New hope for nerve disease: testing better doses of common treatment
NCT ID NCT06752356
Summary
This study aims to find the best dose of a standard immune globulin (IGIV) treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness. Researchers will compare a lower dose (0.5 g/kg) to a standard dose (1.0 g/kg) given every 3 weeks for 21 weeks to see which is more effective at improving disability scores. The goal is to control the disease and improve function for patients who currently depend on treatments like immunoglobulins or steroids.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Neurology Epilepsy and Sleep Center/ANESC Research
RECRUITINGEl Paso, Texas, 79912, United States
Conditions
Explore the condition pages connected to this study.